Wanbury Limited has secured regulatory approvals from key global health authorities, strengthening its position in the active pharmaceutical ingredient (API) market. The company received approval from the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its Rivaroxaban API. Additionally, Wanbury obtained Drug Master File (DMF) clearances from the US Food and Drug Administration (USFDA) for two APIs: Paroxetine HCl and Metformin HCl.

The press release, issued on August 13, 2026, pursuant to Regulation 30 of SEBI LODR, highlights that these approvals are critical for expanding the company's addressable market. The EDQM approval enables Wanbury to meet customer demand in the European Union and other countries that accept the Certificate of Suitability to the European Pharmacopoeia Monograph (CEP). Meanwhile, the USFDA DMF clearances were received while Anda (Abbreviated New Drug Application) reviews are underway for multiple customers, facilitating supply chain integration for finished dosage form manufacturers in the United States.

Regulatory approvals at a glance

The three clearances span two of the most stringent pharmaceutical regulatory frameworks globally. The following table summarises the specific approvals received:

Significance of the approvals

Rivaroxaban is an anticoagulant used in the management of blood clotting disorders. Paroxetine HCl is an antidepressant, and Metformin HCl is widely prescribed for type 2 diabetes management. These therapeutic categories represent significant global markets with consistent demand.

EDQM approval is a prerequisite for marketing APIs in European Union member states, providing a streamlined pathway for regulatory compliance across the region. USFDA DMF clearances are a critical step in the supply chain, allowing generic drug manufacturers to reference Wanbury's API data in their own regulatory submissions. These approvals collectively expand Wanbury's regulatory credentials and potential revenue streams across major geographies.

Wanbury Limited reported a significant contraction in profitability for the quarter ended June 30, 2026, with net profit after tax (PAT) falling 76.0% year-on-year to ₹3.2 crore. The decline was primarily driven by an unprecedented surge in input costs, particularly solvents and crude oil-linked materials, exacerbated by logistics disruptions in West Asia that delayed API export dispatches. Despite these headwinds, revenue from operations grew 1.5% to ₹165 crore, reflecting resilient demand for its active pharmaceutical ingredients (APIs) and domestic formulations.

The company filed its unaudited financial results with the Bombay Stock Exchange and National Stock Exchange of India Ltd under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing highlights a divergence between top-line stability and bottom-line pressure, as gross margins contracted to 52.5% from 54.0% in the corresponding quarter last year. Management attributes this margin erosion to timing mismatches in passing on inflationary costs to customers, a factor expected to resolve in subsequent quarters.

Financial Performance

The table below summarises Wanbury's key financial metrics for the quarter, reflecting the sharp divergence between revenue resilience and profitability compression.

*Includes Other Income

Earnings per share (EPS) dropped to ₹0.93 from ₹4.12 in Q1 FY26. Other income remained modest at ₹0.4 crore, up slightly from ₹0.3 crore in the prior year period. The severe compression in PAT margins — down 631 basis points year-on-year — underscores the immediate impact of supply chain shocks on operational efficiency.

Strategic Developments

Beyond financial metrics, Wanbury executed key strategic initiatives during the quarter. The company completed a refinancing of its debt facilities with Axis Finance Limited and Poonawalla Fincorp, availing aggregate borrowings of ₹205 crore. This move replaced existing high-cost borrowings, reducing the borrowing cost from 12.5% per annum to sub-10% per annum effective July 1, 2026. Consequently, the pledge on promoter shareholding of 1,42,03,818 equity shares (40.65% of paid-up capital) has been released.

Regulatory approvals continued to strengthen the company's global footprint:

• Australia: The Tanuku API manufacturing site cleared inspections by the Therapeutic Goods Administration (TGA), enabling exports of three additional APIs.
• Korea: The Patalganga facility completed Ministry of Food and Drug Safety (MFDS) inspections with zero observations, receiving its GMP certificate during the quarter.
• US: Subsequent to the quarter-end, on July 30, 2026, the USFDA issued a "No DMF deficiency letter" for Metformin HCl API across multiple ANDAs. A Certificate of Suitability for Riveroxaben API was received on July 31, 2026.
• New Markets: DMFs were filed for Diphenhydramine HCl in Malaysia and Singapore, and Paroxetine HCl in Korea and Latin America.

What the Numbers Show

The data reveals a temporary structural disconnect between revenue generation and cost absorption. While revenue growth remained positive at 1.5%, the inability to pass through sudden input cost inflation within the same quarter led to a disproportionate drop in profitability. The successful refinancing signals a reduction in future fixed costs, with management expecting finance cost benefits to flow through from Q2 FY27 onwards. This suggests that the current margin contraction is likely transitory rather than indicative of long-term operational weakness.